Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01447511 · ClinicalTrials.gov registry record · NA
Pharmacogenetics of Warfarin Induction and Inhibition
A NA study, sponsored by University of Minnesota.
- Completed
- Registry status
- NA
- Development phase
- 39
- Enrollment target
NCT01447511 is a NA study that has completed, run by University of Minnesota. The registered enrollment target is 39 participants.
The verdict
NCT01447511, a NA study, has completed, sponsored by University of Minnesota.
- COMPLETED
- Registry status
- NA
- Development phase
- 39 participants
- Enrollment target
Study Summary
This research study will help determine how a person's genetic makeup affects their response to drugs, the ability of the body to break down drugs, and their potential to experience an interaction between drugs. The investigators are investigating the drug interactions with the commonly used anticoagulant drug called warfarin. Warfarin is used for the treatment and prevention of life-threatening abnormal blood clots such as deep vein thrombosis, heart attacks, and strokes. The investigators chose warfarin for this study because it is a commonly used drug and must be monitored closely to avoid side effects. The investigators are interested in studying whether individuals with certain genetic profiles react differently to warfarin when it is combined with other drugs. This research is being done to see if certain genetic profiles require us to adjust warfarin doses differently than is needed for the general population. Genetic profiles of subjects are determined from their participation in the Pharmacogenetics Registry study (investigator Richard Brundage, University of Minnesota). The study hypothesis is: Functionally defective CYP2C9 alleles attenuate the warfarin-fluconazole inhibitory interaction and exacerbate the warfarin-rifampin inductive interaction.
Interventions
- DRUG Control - Warfarin only
- DRUG Fluconazole - Warfarin
- DRUG Rifampin - Warfarin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 39 participants |
| Start Date | 2009-05 |
| Est. Completion | 2013-06 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01447511
The ClinicalTrials.gov registry entry for NCT01447511 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 39 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Minnesota, which has 966 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Control - Warfarin only is the first listed.
NCT01447511 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01447511 about?
NCT01447511 is a clinical study titled "Pharmacogenetics of Warfarin Induction and Inhibition". This research study will help determine how a person's genetic makeup affects their response to drugs, the ability of the body to break down drugs, and their potential to experience an interaction between drugs. The investigators are investigating the drug interactions with the commonly used anticoa...
What is the current status of trial NCT01447511?
This trial is currently completed. It is a NA study. The enrollment target is 39 participants. The study started on 2009-05. Estimated completion is 2013-06.
What interventions are being tested in trial NCT01447511?
The interventions under investigation include: Control - Warfarin only (DRUG), Fluconazole - Warfarin (DRUG), Rifampin - Warfarin (DRUG).
Who is sponsoring clinical trial NCT01447511?
This trial is sponsored by University of Minnesota, which has 966 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.